Docetaxel-based chemohormonal therapy increased tumor-infiltrating T cells by activating the cGAS/STING pathway and IFN signaling, leading to upregulation of PD1/PD-L1 expression and improved PSA progression-free survival in clinical trials. This evidence concerns the gene STING1 and neoplasm.